Jun 30, 2022

Penumbra Q2 2022 Earnings Report

Penumbra's financial performance increased in the second quarter of 2022, with revenue growth driven by vascular products and international sales.

Key Takeaways

Penumbra, Inc. reported a revenue increase of 13.1% in the second quarter of 2022, reaching $208.3 million. Vascular products and international sales were key growth drivers. The company is maintaining its full-year revenue guidance of $860 million to $875 million.

Total revenue increased to $208.3 million, a 13.1% increase compared to Q2 2021.

Revenue from vascular products grew by 22.7% to $123.5 million.

Revenue from neuro products grew by 1.5% to $84.8 million.

The United States accounted for 68% of total revenue, while international sales represented 32%.

Total Revenue
$208M
Previous year: $184M
+13.1%
EPS
$0.01
Previous year: $0.21
-95.2%
Gross Margin
64.3%
Previous year: 64.4%
-0.2%
Gross Profit
$134M
Previous year: $119M
+12.9%
Cash and Equivalents
$58.2M
Previous year: $82.3M
-29.2%
Free Cash Flow
-$44M
Previous year: -$6.61M
+566.3%
Total Assets
$1.33B
Previous year: $910M
+45.9%

Penumbra

Penumbra

Penumbra Revenue by Geographic Location

Forward Guidance

The Company is maintaining its guidance for 2022 total revenue to be in the range of $860 million to $875 million. Due to foreign currency fluctuations, the Company expects total 2022 reported revenue to be at the lower end of this range, however it expects to maintain growth of 15 – 17% over 2021 revenue on a constant currency basis.

Revenue & Expenses

Visualization of income flow from segment revenue to net income